RxDoctor Payments Data

Brianne Symonds

Nurse Practitioner · Corning, NYNPI 1336551019

Payments from drug & device makers

$2,446in general payments, 2019–2025

Across 118 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$473
  • Pfizer$90
  • Abbott$14

What the payments were for

  • Food & beverage$2,446100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca90$1,869
AbbVie23$473
Pfizer4$90
Abbott1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,446 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$42,915
Medicare patients
129
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$135,088
FarxigaDapagliflozin Propanediol108$94,781
MounjaroTirzepatide57$66,051
JardianceEmpagliflozin54$62,617
TrulicityDulaglutide46$58,996
EliquisApixaban54$53,006
RybelsusSemaglutide34$41,419
XareltoRivaroxaban20$32,317
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$27,110
LinzessLinaclotide18$14,487
SymbicortBudesonide/Formoterol Fumarate58$12,960
DapagliflozinDapagliflozin Propanediol23$10,651
Pregabalin57$6,555
Albuterol Sulfate HfaAlbuterol Sulfate155$6,006
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$5,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,869$134,851191 claims
PfizerEliquis$90$53,00654 claims
AbbVieLinzess$473$14,48718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Corning

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →